Business
UNIVERSAL IBOGAINE EXPANDS RESEARCH TEAM WITH JULIE DUMOUCHEL, DIRECTOR OF CLINICAL TRIALS
UNIVERSAL IBOGAINE EXPANDS RESEARCH TEAM WITH JULIE DUMOUCHEL, DIRECTOR OF CLINICAL TRIAL...
About this update from Universal Ibogaine Inc
[{"type":"text","content":"\n \n \n \n UNIVERSAL IBOGAINE EXPANDS RESEARCH TEAM WITH JULIE DUMOUCHEL, DIRECTOR OF CLINICAL TRIALS\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n CALGARY, AB\n \n \n ,\n \n \n March 23, 2022\n \n \n /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) and (OTCQB: IBOGF) (\"UI\" or the \"Company\") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce the key strategic addition of\n \n Julie Dumouchel\n \n as Director of Clinical Trials.  Universal Ibogaine is working towards a planned clinical trial with Health Canada to prove the safety and efficacy of ibogaine for the disruption of opioid addiction.  UI owns the global licensing rights for the ibogaine treatment protocol developed by Dr.\n \n Alberto Sola\n \n , UI Board Member and one of the founders of the Clear Sky Recovery Clinic which has operated an addiction treatment centre in\n \n Cancun, Mexico\n \n since 2007.  Dr Sola has safely administered over 3,700 ibogaine treatments, more than any other doctor in the world.\n \n \n \n \n \n \n \n \n \n \n Julie Dumouchel\n \n brings 25 years in the pharmaceutical industry, where she has held various clinical research roles, developing a deep understanding of the drug development process. Julie is passionate about clinical operations and the drug development process.  Her experience leading strong research teams to advance clinical trials while navigating changing regulations will augment UI's planned business platforms of drug development and clinical service delivery.\n \n \n As Director of Clinical Trials,\n \n Julie Dumouchel\n \n will lead the design, planning and execution of ibogaine clinical trials and related projects. As a pharmaceutical industry executive, Julie has had roles in Clinical Research Organizations such as Quintiles and Santé Cannabis, biotechs including MethylGene (TSX: MYG), Canopy Health Innovations and large pharmaceutical companies including Scheri...